Brighton Jones’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.74M Sell
7,723
-913
-11% -$194K 0.03% 346
2026
Q2
$1.87M Buy
8,636
+585
+7% +$112K 0.03% 320
2026
Q1
$1.48M Buy
+8,051
New +$1.48M 0.03% 348
2025
Q4
– Sell
-6,514
Closed -$912K – 151
2025
Q3
$912K Buy
6,514
+1,412
+28% +$191K 0.02% 422
2025
Q2
$641K Buy
+5,102
New +$636K 0.02% 456
2022
Q4
– Sell
-809
Closed -$216K – 480
2022
Q3
$216K Buy
+809
New +$172K 0.01% 403
2021
Q4
– Sell
-833
Closed -$236K – 534
2021
Q3
$236K Buy
+833
New +$273K 0.01% 419
2018
Q4
– Sell
-570
Closed -$201K – 264
2018
Q3
$201K Buy
+570
New +$196K 0.02% 273
2015
Q3
– Sell
-632
Closed -$255K – 195
2015
Q2
$255K Sell
632
-1
-0.2% -$401 0.06% 154
2015
Q1
$267K Buy
633
+20
+3% +$7.88K 0.06% 150
2014
Q4
$208K Sell
613
-510
-45% -$165K 0.05% 181
2014
Q3
$371K Sell
1,123
-22
-2% -$7.25K 0.08% 128
2014
Q2
$361K Buy
1,145
+10
+0.9% +$3.01K 0.08% 125
2014
Q1
$347K Buy
1,135
+81
+8% +$25.7K 0.08% 122
2013
Q4
$295K Buy
1,054
+66
+7% +$17.1K 0.07% 135
2013
Q3
$238K Buy
+988
New +$221K 0.06% 134

Other funds holding BIIB

Brighton Jones's BIIB Position: Q3 2026 in Review

Brighton Jones reduced its Biogen (BIIB) stake by 11% in Q3 2026, selling an estimated $194K and leaving 7,723 shares worth $1.74M. The position accounts for 0.03% of the portfolio, ranked #346.

Brighton Jones first reported a position in BIIB in Q3 2013 and has held it in 16 quarters since. The position peaked at $1.87M in Q2 2026. 881 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Brighton Jones held 7,723 shares of Biogen worth $1.74M as of Q3 2026.
  • Brighton Jones sold 913 Biogen shares in Q3 2026, an estimated $194K.
  • Biogen made up 0.03% of Brighton Jones's portfolio in Q3 2026, its #346 holding.
  • Brighton Jones first reported a position in Biogen in Q3 2013 and has held it in 16 quarters since.
  • Brighton Jones's Biogen position peaked at $1.87M in Q2 2026.
  • 881 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.